Uncategorized

Genmab A/S announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide showed an overall response rate of 98 percent and complete metabolic response of 87 percent in response evaluable patients with relapsed or refractory follicular lymphoma.

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that both pivotal trials for exagamglogene autotemcel in patients with transfusion-dependent beta thalassemia or severe sickle cell disease met primary and key secondary endpoints at pre-specified interim analyses.

ImmunoGen Inc. announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine in patients with frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.

Faron Pharmaceuticals Oy announces the release of new biomarker data from the ongoing Phase I/II BEXMAB study of bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia and myelodysplastic syndrome.

Immunovia AB announces that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.

Elevation Oncology, Inc. announced the pricing of an underwritten public offering of 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000 shares of common stock and accompanying warrants to purchase one share of common stock for each

On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent Protein Vaccine developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China.

Astellas Pharma Inc. announced the submission of a New Drug Application on June 9, 2023 to Japan’s Ministry of Health, Labour and Welfare for zolbetuximab, a first-in-class investigational Claudin 18.2 -targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2-positive.

More than half of respondents to a survey from Tata Consultancy Services saw wide implementation of digital twins in life sciences and healthcare in the next three years.

The FDA’s marketing authorization for Cue’s COVID-19 molecular test could boost consumer access, but the company faces strong competition from more established diagnostic firms.